Thanks to growing demand for Healthcare-Big Data and steady growth in Tele-medicine and Dispensing Pharmacy Support, performance was good in terms of results and major KPIs.
Consolidated revenue
(Million JPY)
9,550
Y-o-Y
+37%
Consolidated EBITDA
(Million JPY)
2,472
Y-o-Y
+49%
Healthcare-
Big Data
Y-o-Y
+50%
Tele-medicine and
Dispensing
Pharmacy Support
Y-o-Y
Tele-medicineDispensing Pharmacy Support
+13% +33%
Number of the population
of contracted health
insurance unions
9.88 mil people
Number of Pep Up IDs
3.01 mil people
Estimation of the number of continually-contracted health insurance unions and the number of issued IDs at end of September 2021
Revenue of
Healthcare-Big Data
Average revenue of
Top 10 customers
+50%
Comparison of LTM for September 30, 2020 and LTM for September 30, 2021
4
Note: IFRS-based
EBITDA: Operating profit + Depreciation and amortization costs ± Other profits and/or losses
LTM: Last Twelve Months (the past 12 months from the latest quarter)
(Reference) The JMDC Group's Business Segments
Healthcare-Big Data fared well, while the impact of COVID-19 infections on Tele-medicine and Dispensing Pharmacy Support continued in part.
Healthcare-Big Data
Tele-medicine
Dispensing Pharmacy
Support
Business outline
Remarks
For Industry
• Consulting service for pharmaceutical companies and insurance
Data utilization service for pharmaceutical companies
companies expanded steadily.
and insurance companies
• Launched the provision of pharmacy-derived data
For Payers and individuals
• Adoption of Pep Up accelerated, with the number of issued IDs
Data analysis for health insurance unions and
exceeding three million.
provision of ICT product "Pep Up" to health
• Expanded the functions of Pep Up (vaccination records,
insurance union members
prescription notebooks, etc.)
For Medical Service Providers
• Expanded the service for medical institutions as ICM joined our
Data analysis, system provision, consulting and
Group
finance for medical institutions as well as
• Launched "Ishiyaku," an app for doctors, and embarked on the
platforms for doctors
development of a platform for doctors as Antaa joined our Group
• Demand dropped more sharply than expected due to the fifth wave
Provision of the remote diagnostic imaging service
of COVID-19 infections, but the performance was good compared
to last year
• Expanded the business via M&As despite lower investments by
Development/provision of receipt computer and
dispensing pharmacies
electronic medication history for pharmacies
• Started an initiative toward the commercialization of an AI-driven
optimized medicine inventory management service
5
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
Original document
Permalink
Disclaimer
JMDC Inc. published this content on 05 November 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 05 November 2021 06:11:25 UTC.
JMDC Inc. is a Japan-based company mainly engaged in the health big data business, telemedicine business and dispensing pharmacy support business. The Company operates in three business segments. The Health Big Data segment is engaged in the provision of receipt data analysis and health promotion solutions, and personal health information platforms, the build, management and analysis of medical databases such as receipt data and medical examination data, the build and sale of drug databases, and the development and provision of systems using drug databases for medical institutions. The Telemedicine segment is engaged in the provision of remote image diagnosis matching services, and infrastructure systems for remote image diagnosis. The Dispensing Pharmacy Support segment is engaged in the development and provision of business systems and electronic medication record for dispensing pharmacies, as well as the operation of dispensing pharmacies.
JMDC INC. 
